HuMax-IL8™ (formerly called HuMax-Inflam) is a high-affinity human antibody directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. IL-8 is a major mediator of inflammation, a potent chemoattractant for white blood cells called neutrophils, as well as an important factor in angiogenesis. HuMax-IL8 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophils from migrating towards sites of inflammation via a process known as chemotaxis. HuMax-IL8 also potently inhibits IL-8 induced neutrophil activation. In pre-clinical studies, HuMax-IL8 has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice.

Genmab will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD) and pustular dermatoses.

Palmoplantar Pustulosis   

Previous Clinical Studies

Phase I/II Results
In this non-placebo, controlled, ascending dose Phase I/II study, a total of 31 patients with palmoplantar pustulosis received an initial single dose of 0.15, 0.5, 1, 2, 4, or 8 mg/kg of HuMax-IL8. Following a satisfactory safety review, 29 patients entered a repeat dose extension study receiving four doses at weekly intervals. Fifty-seven percent (16 of 28) of patients who completed the study achieved a 50% or more reduction. No dose limiting toxicity was reported after administration of doses up to 8 mg/kg, and it is believed that the maximum tolerated dose was not reached.